United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
400.52
+20.05 (5.27%)
At close: Sep 5, 2025, 4:00 PM
407.00
+6.48 (1.62%)
After-hours: Sep 5, 2025, 7:14 PM EDT
United Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover United Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $441.13, which forecasts a 10.14% increase in the stock price over the next year. The lowest target is $302 and the highest is $600.
Price Target: $441.13 (+10.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 2 | 2 | 3 | 3 | 3 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $510 → $575 | Buy | Maintains | $510 → $575 | +43.56% | Sep 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $400 → $500 | Strong Buy | Maintains | $400 → $500 | +24.84% | Sep 5, 2025 |
| UBS | UBS | Strong Buy Maintains $415 → $560 | Strong Buy | Maintains | $415 → $560 | +39.82% | Sep 4, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $295 → $414 | Hold | Maintains | $295 → $414 | +3.37% | Sep 3, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $432 → $564 | Strong Buy | Maintains | $432 → $564 | +40.82% | Sep 2, 2025 |
Financial Forecast
Revenue This Year
3.28B
from 2.88B
Increased by 13.89%
Revenue Next Year
3.46B
from 3.28B
Increased by 5.68%
EPS This Year
27.70
from 24.64
Increased by 12.44%
EPS Next Year
28.66
from 27.70
Increased by 3.46%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.5B | 3.8B | |||
| Avg | 3.3B | 3.5B | |||
| Low | 3.1B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.4% | 15.3% | |||
| Avg | 13.9% | 5.7% | |||
| Low | 6.5% | -8.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.85 | 33.01 | |||
| Avg | 27.70 | 28.66 | |||
| Low | 24.75 | 23.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.2% | 19.2% | |||
| Avg | 12.4% | 3.5% | |||
| Low | 0.4% | -16.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.